OXFORDSHIRE, England—(BUSINESS WIRE)—Oct. 27, 2005—
Celoxica, the leading provider of C-based electronic
system level (ESL) design and synthesis solutions, today announced its
admission to the Alternative Investment Market (AIM) of the London
Stock Exchange (LSE) and the commencement of trading in its Ordinary
Shares. Trading under the symbol CXA, the Company raised GBP 6.1M
($10.9M USD).
Based in the UK near Oxford, Celoxica is the leading provider of
electronic system level (ESL) design and synthesis solutions used for
the design and development of complex electronic products and embedded
systems. According to Gartner, ESL is set to become a major driver of
growth for the broader electronic design automation (EDA) market and
could be worth as much as $1.6 billion by 2009. Celoxica addresses a
key requirement in the success of ESL; the implementation of hardware
directly from complex algorithms written in C-software descriptions.
"We are pleased that the investment community has recognized our
potential and AIM listing is an important step in Celoxica's strategic
development," said Phil Bishop, CEO of Celoxica. "The growing
complexity of digital electronics combined with challenging and
aggressive development schedules are increasing the demand for our
design solutions, a trend that is predicted to continue."
About Celoxica
An innovator in Electronic System Level (ESL) design, Celoxica is
turning software into silicon by supplying the design tools, boards,
IP and services that enable the next generation of advanced electronic
product design. Celoxica technology raises design abstraction to the
algorithm level, accelerating productivity and lowering risk and costs
by generating semiconductor hardware directly from C-based software
descriptions. Adding to a growing installed base, Celoxica provides
the world's most widely used C-based behavioral design and synthesis
solutions to companies developing semiconductor products in markets
such as consumer electronics, defense and aerospace, automotive,
industrial and security. For more information, visit:
www.celoxica.com.
Celoxica and the Celoxica logo are trademarks of Celoxica Holdings
plc. All other brand names and product names are the property of their
respective owners.
Contact:
Celoxica Ltd.
Jeff Jussel, 512-795-8170
Email Contact
or
VitalCom Marketing & PR
Karen Tyrrell, 650-366-8212 ext. 204
Email Contact
or
Neesham PR
Peter van der Sluijs, +44-1442-879-222
Email Contact
Be the first to review this article
